SEL rhBDNF
Alternative Names: SEL-rhBDNFLatest Information Update: 25 Feb 2025
At a glance
- Originator Manzanita Pharmaceuticals
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Nerve growth factors
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Optic nerve glioma
Most Recent Events
- 09 Sep 2024 Early research in Optic nerve glioma in USA (Intracisternal), prior to September 2024 (Manzanita Pharmaceuticals pipeline, September 2024)
- 09 Sep 2024 Early research in Optic nerve glioma in USA (Intravitreous), prior to September 2024 (Manzanita Pharmaceuticals pipeline, September 2024)